Background: By modulating the estrous cycle, numerous oestrus-inducing or synchronising therapeutic hormones and medicines are accessible for pharmacological use, allowing for rapid onset of estrus in the majority of animals.
Objective: The purpose of this research is to evaluate the efficacy of Nano-Lipid containing prostaglandin F2 nanotechnology in synchronising the estrous cycle.
Material and Methods: The strategy to induce and synchronise estrus75 in 4- to 8-week-old female mice was tested in an animal investigation to establish its efficacy across three treatment groups: control, conventional, and SNLPGF2. The first group received a saline injection as a control, the second group received conventional hormone injections at 5, 10, 15, 20, and 25 IU g/kg body weight (I.P. ), and the third group received SNL PGF2 hormone injections at 5, 10, 15, 20, and 25 IU g/kg body weight I.M.
Results: Nano-lipid Size The PGF2 ranged in length from 50 to 166.6 nm. whereas SNL PgF2 trapping efficiency is 84.11 (SD 5.55). As expected, autolysis and a rise in the estrus phase and an increase in the amount of estrogen were responsible for the greatest degree of synchronisation in the group that received large doses of nano-treatment.
Conclusion: results of this research demonstrate that Prostaglandin F2 f Nano-lipid has a high efficiency for synchronising the estrous cycle.